Search Results - "Gilson, Martyn J."

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial by Roufosse, Florence, Kahn, Jean-Emmanuel, Rothenberg, Marc E., Wardlaw, Andrew J., Klion, Amy D., Kirby, Suyong Yun, Gilson, Martyn J., Bentley, Jane H., Bradford, Eric S., Yancey, Steven W., Steinfeld, Jonathan, Gleich, Gerald J.

“…Anti–IL-5 therapy is a potential treatment for patients with hypereosinophilic syndrome (HES), although its clinical efficacy is unclear. We sought to…”
Get full text

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study by Lugogo, Njira, MD, Domingo, Christian, MD, Chanez, Pascal, MD, PhD, Leigh, Richard, MBChB, Gilson, Martyn J., MSc, Price, Robert G., MSc, Yancey, Steven W., MSc, Ortega, Hector G., MD

“…Abstract Purpose Patients with severe eosinophilic asthma often experience recurrent asthma exacerbations despite intensive inhaled corticosteroid therapy. In…”
Get full text

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) by Moore, Wendy C, Kornmann, Oliver, Humbert, Marc, Poirier, Claude, Bel, Elisabeth H, Kaneko, Norihiro, Smith, Steven G, Martin, Neil, Gilson, Martyn J, Price, Robert G, Bradford, Eric S, Liu, Mark C

“…The long-term efficacy and safety of mepolizumab for treatment of severe eosinophilic asthma are well established. Here, we examine the clinical impact of…”
Get full text

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study by Khurana, Sandhya, MD, Brusselle, Guy G., MD, PhD, FERS, Bel, Elisabeth H., MD, FitzGerald, J. Mark, MD, Masoli, Matthew, MD, Korn, Stephanie, MD, Kato, Motokazu, MD, PhD, Albers, Frank C., MD, PhD, Bradford, Eric S., MD, Gilson, Martyn J., MSc, Price, Robert G., MSc, Humbert, Marc, MD, PhD

“…AbstractPurposeThe goal of this study was to assess the long-term safety and efficacy of mepolizumab in patients with the most severe eosinophilic asthma…”
Get full text

Long-Term Safety and Efficacy of Mepolizumab in Patients with Severe Eosinophilic Asthma by Albers, Frank C., MD, PhD, Lugogo, Njira, Gilson, Martyn J, Price, Robert, Yancey, Steven W

“…Methods Following completion of MEA115588 and MEA115575 (both double-blind studies), 651 patients with severe eosinophilic asthma entered a 52-week open-label…”
Get full text